

Cover Story
Relying largely on maturing data from the European trials of screening for prostate cancer, the U.S. Preventive Services Task Force has given a better grade—a “C”—to screening for prostate cancer.
By Matthew Bin Han Ong
In Brief
Funding Opportunities
Clinical Roundup
Drugs & Targets
Trending Stories
- From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - Trump’s tariffs on generic drugs are “another wrinkle in an already unstable system”
- A new AI tool enables speedy use of ASCO guidelines, eliminating typical errors
- NCAB asks for help from administration as NCI deals with deluge of grant applications
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case




















